Cargando…

Pre-operative ctDNA predicts survival in high-risk stage III cutaneous melanoma patients

BACKGROUND: The outcomes of patients with stage III cutaneous melanoma who undergo complete surgical resection can be highly variable, and estimation of individual risk of disease recurrence and mortality remains imprecise. With recent demonstrations of effective adjuvant targeted and immune checkpo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, J H, Saw, R P, Thompson, J F, Lo, S, Spillane, A J, Shannon, K F, Stretch, J R, Howle, J, Menzies, A M, Carlino, M S, Kefford, R F, Long, G V, Scolyer, R A, Rizos, H
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2019
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6551453/ https://www.ncbi.nlm.nih.gov/pubmed/30860590 http://dx.doi.org/10.1093/annonc/mdz075

Ejemplares similares

Design and Testing of a Custom Melanoma Next Generation Sequencing Panel for Analysis of Circulating Tumor DNA
por: Diefenbach, Russell J., et al.
Publicado: (2020)

Analysis of the Whole-Exome Sequencing of Tumor and Circulating Tumor DNA in Metastatic Melanoma
por: Diefenbach, Russell J., et al.
Publicado: (2019)

Anchored Multiplex PCR Custom Melanoma Next Generation Sequencing Panel for Analysis of Circulating Tumor DNA
por: Diefenbach, Russell J., et al.
Publicado: (2022)

Current management of patients with melanoma who are found to be sentinel node‐positive
por: Nijhuis, Amanda A. G., et al.
Publicado: (2019)

Clinicopathological Characteristics Predicting Further Recurrence and Survival Following Resection of In-Transit Melanoma Metastases
por: Lawless, Anna K., et al.
Publicado: (2022)

Tumor MHC Expression Guides First-Line Immunotherapy Selection in Melanoma
por: Shklovskaya, Elena, et al.
Publicado: (2020)

Improving Selection for Sentinel Lymph Node Biopsy Among Patients With Melanoma
por: Miller, James R., et al.
Publicado: (2023)

Evaluation of two high-throughput proteomic technologies for plasma biomarker discovery in immunotherapy-treated melanoma patients
por: Lim, Su Yin, et al.
Publicado: (2017)

Correlation of BRAF and NRAS mutation status with outcome, site of distant metastasis and response to chemotherapy in metastatic melanoma
por: Carlino, M S, et al.
Publicado: (2014)

Adjuvant therapy with high dose vitamin D following primary treatment of melanoma at high risk of recurrence: a placebo controlled randomised phase II trial (ANZMTG 02.09 Mel-D)
por: Saw, Robyn PM, et al.
Publicado: (2014)

Transcriptional downregulation of MHC class I and melanoma de- differentiation in resistance to PD-1 inhibition
por: Lee, Jenny H., et al.
Publicado: (2020)

Clinical significance of intronic variants in BRAF inhibitor resistant melanomas with altered BRAF transcript splicing
por: Pupo, Gulietta M., et al.
Publicado: (2017)

BRAF(V600E) protein expression and outcome from BRAF inhibitor treatment in BRAF(V600E) metastatic melanoma
por: Wilmott, J S, et al.
Publicado: (2013)

Unveiling the tumor immune microenvironment of organ-specific melanoma metastatic sites
por: Conway, Jordan W, et al.
Publicado: (2022)

Cross-platform comparison of immune signatures in immunotherapy-treated patients with advanced melanoma using a rank-based scoring approach
por: Mao, Yizhe, et al.
Publicado: (2023)

Diagnostic Accuracy of Fine Needle Biopsy for Metastatic Melanoma and Its Implications for Patient Management
por: Doubrovsky, Anna, et al.
Publicado: (2007)

Higher polygenic risk for melanoma is associated with improved survival in a high ultraviolet radiation setting
por: Seviiri, Mathias, et al.
Publicado: (2022)

Identification of new prognostic biomarkers for Stage III metastatic melanoma patients
por: Kakavand, Hojabr, et al.
Publicado: (2013)

Multiplex melanoma families are enriched for polygenic risk
por: Law, Matthew H, et al.
Publicado: (2020)

Liquid biomarkers in melanoma: detection and discovery
por: Lim, Su Yin, et al.
Publicado: (2018)

Evaluation of stromal HGF immunoreactivity as a biomarker for melanoma response to RAF inhibitors
por: Lezcano, Cecilia, et al.
Publicado: (2014)

Targeted BRAF Inhibition Impacts Survival in Melanoma Patients with High Levels of Wnt/β-Catenin Signaling
por: Chien, Andy J., et al.
Publicado: (2014)

The molecular and functional landscape of resistance to immune checkpoint blockade in melanoma
por: Lim, Su Yin, et al.
Publicado: (2023)

Clinicopathological characteristics of new primary melanomas in patients receiving immune checkpoint inhibitor therapy for metastatic melanoma
por: Pennington, Thomas E, et al.
Publicado: (2022)

Inter- and Intra-Patient Heterogeneity of Response and Progression to Targeted Therapy in Metastatic Melanoma
por: Menzies, Alexander M., et al.
Publicado: (2014)

Higher proportions of CD39+ tumor-resident cytotoxic T cells predict recurrence-free survival in patients with stage III melanoma treated with adjuvant immunotherapy
por: Attrill, Grace Heloise, et al.
Publicado: (2022)

OTHR-08. PREDICTION OF RISK OF CENTRAL NERVOUS SYSTEM METASTASIS FOR AJCC 8(TH) EDITION STAGE III MELANOMA PATIENTS
por: Haydu, Lauren, et al.
Publicado: (2019)

Methylated circulating tumor DNA as a biomarker in cutaneous melanoma
por: Diefenbach, Russell J, et al.
Publicado: (2020)

The Impact of Surveillance Imaging Frequency on the Detection of Distant Disease for Patients with Resected Stage III Melanoma
por: Dieng, Mbathio, et al.
Publicado: (2022)

Circulating Tumor DNA Reflects Uveal Melanoma Responses to Protein Kinase C Inhibition
por: Park, John J., et al.
Publicado: (2021)

Functional RET G691S Polymorphism in Cutaneous Malignant Melanoma
por: Narita, N, et al.
Publicado: (2009)

Oncogenic B-RAF(V600E) signaling induces the T-box3 transcriptional repressor to repress E-cadherin and enhance melanoma cell invasion
por: Boyd, Suzanah C., et al.
Publicado: (2012)

Cutaneous melanoma
por: Négrier, S, et al.
Publicado: (2001)

Close proximity of immune and tumor cells underlies response to anti-PD-1 based therapies in metastatic melanoma patients
por: Gide, Tuba N., et al.
Publicado: (2019)

Factors influencing acceptance, adoption and adherence to sentinel node biopsy recommendations in the Australian Melanoma Management Guidelines: a qualitative study using an implementation science framework
por: Smith, Andrea L., et al.
Publicado: (2022)

External validation of a prognostic model to predict survival of patients with sentinel node‐negative melanoma
por: Ipenburg, N. A., et al.
Publicado: (2019)

Interferon Signaling Is Frequently Downregulated in Melanoma
por: Alavi, Sara, et al.
Publicado: (2018)

Cost-Effectiveness of PET/CT Surveillance Schedules to Detect Distant Recurrence of Resected Stage III Melanoma
por: Dieng, Mbathio, et al.
Publicado: (2022)

p16(INK4a)-induced senescence is disabled by melanoma-associated mutations
por: Haferkamp, Sebastian, et al.
Publicado: (2008)

Comparative Genomics Provides Etiologic and Biological Insight into Melanoma Subtypes
por: Newell, Felicity, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_u8nf8nm1q5luaqi7rec15d4h4m